KalVista Pharmaceuticals (KALV) Equity Average (2017 - 2024)
KalVista Pharmaceuticals' Equity Average history spans 9 years, with the latest figure at $149.2 million for Q4 2024.
- For Q4 2024, Equity Average changed N/A year-over-year to $149.2 million; the TTM value through Dec 2024 reached $149.2 million, changed N/A, while the annual FY2020 figure was $90.2 million, 45.57% up from the prior year.
- Equity Average for Q4 2024 was $149.2 million at KalVista Pharmaceuticals, down from $153.4 million in the prior quarter.
- Across five years, Equity Average topped out at $189.7 million in Q3 2024 and bottomed at $61.8 million in Q1 2021.
- The 4-year median for Equity Average is $100.2 million (2023), against an average of $113.2 million.
- The largest annual shift saw Equity Average tumbled 34.12% in 2021 before it soared 91.7% in 2024.
- A 4-year view of Equity Average shows it stood at $69.7 million in 2020, then decreased by 11.38% to $61.8 million in 2021, then soared by 105.42% to $126.9 million in 2023, then rose by 17.56% to $149.2 million in 2024.
- Per Business Quant, the three most recent readings for KALV's Equity Average are $149.2 million (Q4 2024), $153.4 million (Q4 2024), and $189.7 million (Q3 2024).